Cardiex Limited (ASX: CDX) (the Company) is pleased to announce pre-orders for the CONNEQT Arterial Health Assessment, which comes complete with the CONNEQT Pulse vascular biometric monitor, have commenced in the USA.
Following a very successful waitlist campaign for the Pulse, which has seen more than 20,000 sign-ups, combined with a six-part nurturing campaign to this group, exclusive invitations for pre-orders have now commenced.
This key milestone marks the first phase of the Company’s transition to delivering transformative cardiovascular solutions, based on our industry-leading vascular biomarker technology, across a broader range of healthcare markets.
Cardiex CEO Craig Cooper commented:
“This is a pivotal moment for the company as we launch the CONNEQT Pulse, bringing our vascular health technology directly to U.S. consumers for the first time. This phased pre- order rollout allows us to ensure a smooth customer experience while efficiently managing demand and conversions. Reaching this milestone reaffirms the strength of our strategy, and we expect the positive momentum to support revenue growth and accelerate our entry into broader healthcare markets.”
The CONNEQT Pulse is designed to meet the rising demand for comprehensive cardiovascular health monitoring solutions that go beyond traditional blood pressure measurement. With its focus on accessible, personalized health insights, the Pulse is set to become a valuable tool for individuals seeking proactive cardiovascular health management and for clinicians looking to enhance patient care with advanced vascular health metrics.
Cardiex will continue to roll out additional waves of exclusive pre-order invitations to waitlist members over the coming weeks. This phased approach is intended to ensure an efficient pre-order experience, optimize customer support, and prepare for the device’s broader market launch.
Click here for the full ASX Release
This article includes content from CardieX Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
